Strict Criteria in Cancer Clinical Trials Leave Most Patients Out
Recent reviews reveal that clinical trial criteria exclude a large portion of real-world patients, creating a gap between approved drugs and the patient profile.
Strict eligibility criteria in clinical trials cause the majority of real-world cancer patients who use approved drugs to be excluded from these processes.
Obstacles Faced in Clinical Trials
Clinicians working in the treatment of blood cancers state that serious obstacles are encountered in patient participation in clinical trials or access to new drugs. Systematic evaluations show that this situation constitutes a significant bottleneck in treatment processes.
Reviews Conducted with Real-World Data
Researchers examined ongoing clinical trials for common diffuse large B-cell lymphoma processes and applied these criteria to real-world patients. The findings revealed that a significant portion of the patients could not meet the established strict conditions.
Reasons Why Criteria Exclude Patients
Approved clinical trials have varying eligibility criteria ranging from thirty-one to forty-five. Strict requirements such as organ functions, disease burden, and previously received treatments lead to the automatic elimination of numerous patients from the process.
The Balance Between Internal and External Validity
Experts state that clinical trials focus on proving safety and efficacy while prioritizing internal validity and homogeneous populations. This approach generally occurs at the expense of reflecting external validity and real-world patient diversity.